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Substituent eﬀects on the basicity (pKa) of aryl
guanidines and 2-(arylimino)imidazolidines:
correlations of pH-metric and UV-metric values with
predictions from gas-phase ab initio bond lengths†
Christophe Dardonville, *a Beth A. Caine,bc Marta Navarro de la Fuente,a
Guillermo Martı´n Herranz,a Beatriz Corrales Mariblancaa and Paul L. A. Popelier bc
The dissociation constants of two related series of 2-(arylimino)imidazolidine and aryl guanidine
a2-adrenoceptor antagonists (35 compounds in total) were measured by potentiometric titrations and by
UV-spectrophotometry using the 96-well microtitre plate method. The experimental values obtained
using both methods were quite consistent and showed a very good agreement with the pKa values
calculated using the AIBLHiCoS methodology, which uses only a single bond length obtained using
ab initio calculations at a low level of theory. The prediction power of the imidazolidine and guanidine
set of compounds was very good with deviations typically o0.30 and o0.24 pKa units, and a mean
absolute error (MAE) of 0.23 and 0.29, respectively. The study of the quantitative eﬀect of diverse
substituents on the basicity of aryl guanidine and 2-(arylimino)imidazolidine derivatives is useful for
medicinal chemists working with biologically relevant guanidine-containing molecules.
1. Introduction
The guanidine group of the amino acid arginine is ubiquitous
in Nature. In its protonated state, several resonance forms that
delocalize the cationic charge of the guanidinium cation over
the entire functional group contribute to the high basicity
of guanidine (pKaH = 13.6 in water).
1 The H-bonding ability of
guanidine makes this group a valuable tool for the design of
compounds for diﬀerent pharmacological applications such as
DNA binding drugs (e.g. anticancer and antiprotozoal agents),2–11
analgesic compounds,12–14 a1-noradrenaline receptors (e.g. a1-AR
antagonists for the treatment of benign prostate hyperplasia),15
or a2-AR modulators for neuropsychiatric therapies.
16–19
Centrally acting a2-adrenoceptor antagonists are potentially
useful pharmacological tools for the treatment of depression and
schizophrenia.16 Among these, arylguanidines and 2-(arylimino)-
imidazolidines represent an important family of a-adrenoceptor
modulators.16–20 The prototypical example of a (phenylimino)-
imidazolidine drug is a2-AR and imidazoline receptor agonist
clonidine (i.e. N-(2,6-dichlorophenyl)-4,5-dihydro-1H-imidazol-
2-amine) used, among other applications, as an antihyperten-
sive drug and for controlling neuropathic pain (Fig. 1).21 As both
the guanidine and 2-aminoimidazoline groups are strong bases,
they are protonated at physiological pH. Thus, this physico-
chemical property may impair the absorption and/or limit the
uptake of guanidine-containing molecules through biological
membranes, including the blood–brain barrier,22,23 a drawback
that is highly relevant for centrally acting drugs.
The protonation state of a drug molecule determines its
lipophilicity, solubility in biological fluids, ability to cross biological
membranes, degree of protein binding, and its capacity to bind to
biological targets. Hence, knowing the dissociation constants
(pKa) of drugs is crucial because this parameter aﬀects the key
pharmacokinetic properties such as administration, distribution,
metabolism and excretion (ADME).24
One of the objectives of this work is to understand the
quantitative eﬀect of diverse substituents on the aqueous basicity
of pharmacologically important families of compounds: aryl
guanidines and 2-(arylimino)imidazolidines. This knowledge
is useful to assist in the design of new biologically relevant
guanidine-containing molecules with improved pharmacokinetic
properties.22 Another objective is to compare the experimental pKa
values of these series with those obtained by ab initio calculations
using the AIBLHiCoS method.25,26 The Ab Initio Bond Lengths
High Correlation Subsets protocol works on the basis that, for a
series of electronically congeneric compounds, chemical space
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may be partitioned according to a linear free energy relationship
(LFER) between the calculated gas-phase equilibrium bond lengths
and aqueous pKa values. The equations resulting from highly
correlated, local linear relationships for structurally similar mole-
cules are then used as predictive models for calculating the pKa
values of other compounds belonging to the appropriate High
Correlation Subset (HiCoS). In this work, using a specific bond
length and tautomeric form in the neutral state, we have
constructed one predictive model with a training set of 13
guanidines and a second model with a training set of 23
2-(phenylimino)imidazolidines. This method is a valuable tool
that has already proven its power for the accurate determination
of pKas of other guanidine-containing drugs in addition to a
number of other functional groups.25,27–29 However, this method
has not been tested, until now, with the medically relevant
2-(phenylimino)imidazolidine scaffold. The predictive models
built with these series show that the AIBLHiCoS method is an
accurate pKa prediction tool with this pharmacologically important
family of compounds.
2. Results and discussion
2.1. Synthesis
Trifluoroacetate salts of phenylguanidines (1b, 2b, 3b, 6b, 7b,
and 24–27b) and 2-(phenylimino)imidazolidines (2a–10a, and
23a) were synthesized from their Boc-protected precursors using
CF3CO2H/CH2Cl2 as reported (Scheme 1).
7 These Boc-protected
precursors were obtained by a reaction of the corresponding
anilines with N,N0-bis-(tert-butoxycarbonyl)imidazolidin-2-thione
or N,N0-bis(tert-butoxycarbonyl)thiourea and HgCl2/Et3N/DMF.
7
The pyridino derivatives 17–22 were synthesized as hydrochloride
Fig. 1 Resonance forms of the guanidinium and 2-iminoimidazolidinium
cations responsible for the high basicity of these functional groups.
Structure of the archetypal 2-(arylimino)imidazolidine drug clonidine.
Scheme 1 Synthesis of 2a–10a, 23a, 1b–3b, 6b, 7b, and 24b–27b.
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salts by Rozas and co-workers following a procedure similar to
that shown in Scheme 1.30
Compounds 1a and 11a–15a were synthesized as shown in
Scheme 2 following the procedure of Mundla et al.31
2.2. Correlation between experimental pH-metric, UV-metric,
and calculated pKa
The pKa values of two sets of 23 2-(arylimino)imidazolidines
(1a–23a) and 12 arylguanidines (1b, 2b, 3b, 6b, 7b, 17b, 18b,
22b–27b), most of them developed by Rozas and co-workers as
a2-adrenoceptor ligands,
16–20 were measured by potentiometric
titration (i.e. pH-metric) at 25 1C using the Sirius T3 apparatus,
and by spectrophotometry (i.e. UV-metric) using the 96-well
microtitre plate method developed in our group.32 The pKa
values determined with the T3 apparatus were highly consistent
(SDo 0.03, n = 3) whereas the 96-well microtitre plate method
gave somewhat less precise results (SD = 0.02–0.45, n Z 3)
(Table 1).
A good correlation (r2 = 0.993) was observed between the pKa
values measured using spectrophotometry and potentiometry
(Fig. 2A). The pKa diﬀerences observed between both experimental
techniques were generally r0.3 pKa units except for compounds
1a (+0.67), 4a (+0.37), 5a (+0.57), 20a (+0.51), 21a (+0.47), and 22b
(+0.41).
It is known that low aqueous solubility and chromophore
strength can aﬀect the accuracy of experimental pKa determination
for certain bases.34 As all the compounds with greater discrepancies
between UV-metric and pH-metric pKa values have weak chromo-
phores, this could explain the lack of accuracy with these
compounds. In contrast, if we take the nitro derivatives 11a–15a
as an example of compounds with a strong chromophore and a
smooth transition from the protonated (lmaxE 298 nm at pH 3) to
the neutral form (lmax E 364 nm at pH 12), we observe an
excellent correlation between the UV-metric and pH-metric values
(Table 1).
The pKa values calculated using the AIBLHiCoS methodology
correlated well (r2 = 0.965) with the experimental results obtained
using pH-metric titrations (see Fig. 2B) with deviationso0.30 pKa
units for the phenyl-imidazolidine derivatives. However, some
deterioration was observed for pyridinyl compounds (o0.58) and
two compounds containing nitro groups, 13a (0.79) and 15a
(0.62), were also poorly predicted and are discussed in the
next section. The mean absolute error (MAE) was found to be
0.23 with a standard deviation of 0.22 for the error values using
the model which returned the highest validation statistics
during calibration (C–N(im), Fig. S1, ESI†). This may be compared
to the MAE value for ChemAxon predictions using the imino
tautomer, which was found to be 0.77, with a standard deviation
of 0.47 (Table S1 in the ESI†). The prediction power with the
guanidine set of compounds was slightly lower with an MAE of
0.29, and most deviationsr0.24 pKa units except for compounds
17b (0.55), 24b (+0.70) and one very high error for 22b (+1.05),
which will also be discussed in the next section (Table S2, ESI†).
Finally, with respect to the UV-metric pKa values, deviations
r0.52 pKa units were observed against the predictions of
AIBLHiCoS (and r2 = 0.947) with the exception of compounds
5a (+0.58), 13a (0.94), 15a (0.58), 21a (+0.56) and 22a (0.59)
(Fig. 2C).
2.3. Validation of the AIBLHiCoS prediction method applied
to arylguanidines and 2-(arylimino)imidazolidines
The bond length vs. pKa model used for most of the imidazo-
lidine predictions in this work was chosen on the basis of its
superior r2, leave-one-seventh-out-q2 and Root Mean Error of
Estimation (RMSEE) values compared to a number of other
candidate bond length models. For the 22 compounds of the
training set (listed 1i–22i in Table S3, ESI†), the highest validation
statistics correspond to a model constructed using a C–N bond
length of the imidazolidine ring, when compounds were
represented as the imino tautomer ‘‘T3’’. This model is labelled
C–N(im) in Fig. S1 (ESI†) and will be referred to as such
throughout the following discussion. The second best validation
statistics were observed for the N–C(Ph) bond, which is also
labelled as such in Fig. S1 (ESI†). Predictions using both models
are also listed in Table 1.
For guanidines, superior validation statistics for the training
set (listed g1–g13 in Table S4, ESI†) were obtained using the
CQN bond length with compounds represented as amino
tautomer ‘‘A’’, as illustrated in Fig. S2 (ESI†). All predictions
listed in Table 1 and Table S2 (ESI†) were obtained using
this model.
A high degree of prediction accuracy in modern terms is
considered to be within 1 pKa unit per prediction, with a mean
absolute error (MAE) for a test set of less than 0.5 units.35 As the
Scheme 2 Synthesis of 1a and 11a–15a.
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Table 1 pKa values of aryl/pyridinyl guanidines and iminoimidazolidines calculated using AIBLHiCos and determined experimentally by potentiometric
and spectrophotometric methods
Cmpd Structure Predicted pKa C–N(im)
a pKa N–C(Ph)
d pH-metric pKa
b UV-metric pKa
c
1a 10.549.90 10.24  0.001 10.91  0.10
2a 10.349.89 10.49  0.01 —
3a 10.169.78 10.29  0.01 10.40  0.13
4a 10.339.89 10.42  0.001 10.79  0.10
5a 10.499.94 10.50  0.01 11.07  0.15
6a 10.549.97 10.44  0.01 10.27  0.17
7a 10.7610.26 10.78  0.01 10.91  0.09
8a 10.6710.16 10.62  0.01 10.80  0.13
9a
10.16
9.73 10.17  0.01 10.28  0.45
10a 8.908.79 9.11  0.001 9.42  0.02
11a 8.548.26 8.52  0.001 8.37  0.06
12a 7.287.48 7.29  0.07
e 7.33  0.03
13a 7.288.01 8.07  0.001 8.06  0.07
14a 7.607.32 7.41  0.001 7.41  0.02
15a 7.187.89 7.80  0.001 7.69  0.06
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Table 1 (continued )
Cmpd Structure Predicted pKa C–N(im)
a pKa N–C(Ph)
d pH-metric pKa
b UV-metric pKa
c
16a 9.509.30
8.99  0.001
3.05  0.01f
8.99  0.24
3.11  0.17
17a
9.95
9.54
9.37  0.001
4.36  0.001f
9.57  0.32
4.37  0.19
18a 10.6310.02
10.33  0.001
4.97  0.001f
10.35  0.42
4.96  0.08
19a 9.177.65 9.45  0.001
g 9.60  0.06
20a
9.46
7.81 9.47  0.01
g 9.98  0.05
21a 9.597.91 9.68  0.001
g 10.15  0.15
22a 8.517.30 8.97  0.001
g 9.10  0.09
23a 8.839.14 9.08  0.01
e 9.26  0.06
1b 11.01 10.90  0.001h —
2b 11.22 11.36  0.01 —
3b 11.10 10.98  0.001 10.95  0.25
6b 11.15 10.98  0.001 —
7b 11.24 11.35  0.01 —
17b 10.60 10.05  0.0014.44  0.001f
N/A
4.13  0.35
18b 10.77 11.01  0.014.94  0.01f
N/A
4.98  0.09
22b 10.52 10.47  0.001g 10.88  0.08
24b 11.31 12.01  0.033.63  0.001 —
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training sets consist of pKa values taken from various sources,
and therefore contain measurements obtained using diﬀerent
techniques, noise within the experimental datasets is to be
expected. Small variations in conditions are also possible, i.e.
solvent purity, sample purity and lab temperature, which can
also have an eﬀect on the values measured. According to the
above conditions, the error statistics for both test sets show that
both the guanidine and imidazolidine AIBLHiCoS models
perform well. On only one occasion does any error exceed
1 unit, and the MAE values for both test sets are well below
0.5 (0.23 for imidazolidines and 0.29 for guanidines). For
predictions made using the pKa predictor plug-in within the
Marvin Suite by ChemAxon,36 with the imino tautomer as the
input structure (Tables S1 and S2, ESI†), nine prediction errors
exceed 1.0 pKa units and the MAE values are in excess of
0.5 units for both imidazolidines and guanidines (0.77 and
0.54). AIBLHiCoS therefore finds its place here as a useful tool
in instances where the empirical tools with a wider applicability
radius struggle, as is the case for these guanidine-type ionisable
groups.
2.3.1. Imidazolidines. A particular instance of where AIBL-
HiCoS performs notably well compared to ChemAxon is for the
imidazolidine compounds 11a–15a, all of which contain nitro
groups at the para position of the phenyl ring. ChemAxon
underestimates the acidity of these compounds by +1.23,
+1.64, +1.18, +1.23 and +1.41 units, whereas the AIBLHiCoS
model provides errors of +0.02, +0.01, 0.79, +0.19 and 0.62.
However, two of the largest prediction errors of the imidazolidine
test set correspond to those for 13a and 15a, 2-(3-chloro-4-nitro-
phenylamino) and 2-(3-fluoro-4-nitro-phenylamino)imidazolidine.
Errors for the pH-metric measurements are 0.79 and 0.62, and
compared to the UV-metric values they also give errors of0.94 and
0.58. The resonance-induced strong electron-withdrawing eﬀect of
nitro groups is known to perturb active bond lengths to such an
extent that compounds containing these groups often form their
own separate HiCoS.28,29 Contrary to the previous results, the
partitioning of the imidazolidine set into more structurally specific
subsets may not be defined in this case by the presence of a
nitro group at the para-position. This is explained by the fact
that compound 7i, (2-(2,6-Cl2,4-NO2-phenylimino)imidazolidine),
is present within the training set used to form the predictive
HiCoS, and 11a, 12a and 14a of the test set fall in the expected
region of the trend line for the LFER, as illustrated by their low
prediction errors. According to the LFER exhibited between the
C–N(im) bond length and pKa, a shorter equilibrium bond
length simply corresponds to a lower pKa. In the case of 13a
and 15a, we therefore observe an anomalously short C–N(im)
bond, resulting in lower pKa values than we would expect
according to the LFER exhibited by most other congeners.
Looking to the optimised structures for 13a and 15a to
explain these short bond lengths reveals the presence of an
interaction between the O atom of the p-nitro group, and the
m-Cl (13a) and m-F (15a) atoms. As a result of this interaction,
the nitro group is seen to adopt a geometry whereby it is no
longer co-planar with benzene. It may be asserted that the
presence of this substituent interaction and deviation in nitro
geometry, which is absent in all remaining p-nitro compounds,
may be the cause of the anomalously short C–N(im) bond lengths.
The internal and external validation statistics for the chosen
model (C–N(im)) are superior to any other bond length vs. pKa
plot (r2 = 0.97, q2 = 0.96 and RMSEE = 0.23). The next best
model according to these validation statistics is observed for
the same imidazolidine training set with compounds in the
imino tautomeric form, but for the C–N bond length connecting
benzene to 2-iminoimidazolidine (marked as N–C(Ph) within the
structure labelled ‘‘T3’’ in Fig. S1, ESI†). This model has an r2
value of 0.96, a q2 value of 0.96 and a RMSEE value of 0.25. When
the linear equation for this alternative model is used to predict
for the whole test set 1a–23a, the resultant MAE is significantly
worse than the original model we chose to implement based on
its superior statistics (the MAE is now 0.57 vs. 0.23).
For the 3-pyridyl compounds synthesized in this work,
16a–18a, we observe errors of +0.51, +0.58 and +0.30 for the
pH-metric measurements and 0.51, +0.38 and +0.28 for the
UV-metric values. Despite the increase in MAE when the whole
set is considered, use of the alternative N–C(Ph) model is seen
to reduce the errors for 16a and 17a to 0.31 and +0.17. This
improvement of predicted values can also be seen for the
Table 1 (continued )
Cmpd Structure Predicted pKa C–N(im)
a pKa N–C(Ph)
d pH-metric pKa
b UV-metric pKa
c
25b 11.79 11.68  0.01 11.70  0.09
26b 10.89 11.03  0.01 11.23  0.15
27b 11.03 11.01  0.01 11.12  0.15
a Calculated using the AIBLHiCos approach with the C–N(im) bond model of the imino tautomer. b pH-metric determination at 25 1C using Sirius
T3 apparatus. Mean of 3 titrations  SD. c Determined by UV-spectrophotometry at 30 1C using the 96-well microtiter plate method.32 Mean ofZ 3
titrations  SD. d Bond length model built from the same imidazolidine training set with compounds in the imino tautomeric form, but with the
C–N(Ph) bond length connecting 2-iminoimidazolidine to benzene. e psKa measured with MeOH as a co-solvent (Yasuda–Shedlowsky extrapolation
in H2O).
f pKa value of the pyridin-3-yl nitrogen.
g The pKa value of the pyridin-2-yl nitrogen could not be worked out.
h Literature: pKa = 10.77.
33
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problematic nitro compounds, 13a and 15a, for which the errors
decrease dramatically when predicted using the N–C(Ph) model
(0.26, +0.19, +0.06, 0.09 and +0.09 for 11a–15a).
We now take a moment to briefly introduce the Interacting
Quantum Atoms (IQA) energy partitioning scheme in accordance
with the Quantum Theory of Atoms in Molecules (QTAIM).37,38
By partitioning the total energy of a system into intra- and
interatomic terms, it has been shown that we may derive a
quantitative measure of covalent-like interactions between
atoms in molecules. This comes in the form of the exchange–
correlation potential energy V ABxc , which is the sum of the
exchange energy V ABx and the correlation energy V
AB
c . The former
term dominates V ABxc , and expresses the Fock–Dirac exchange, a
consequence of the Pauli Principle, which describes the ever
reducing probability of finding two electrons of the same spin as
they approach each other (i.e. the Fermi hole). The latter term
V ABc is associated with the Coulomb hole, which corresponds to
the electrostatic repulsion between electrons. The absolute value
of VABxc between two atoms can be taken as the extent of
delocalization of electrons between them, a factor that also
determines the bond distance.
For the training set compounds, for C–N(im) and N–C(Ph),
the VCNxc values (Table S5, ESI†) for the bonded atoms are found
to have r2 values of 0.990 and 0.992 with the corresponding
bond lengths (Fig. S3(a) and (d), ESI†). However, the analogous
plots for other bonds (marked ‘‘b’’ and ‘‘c’’ in Fig. S1 and (b and
c) in Fig. S3, ESI†) have weaker correlations (r2 = 0.939 and
0.897). Therefore, we can conclude that the bond lengths that
correlate most highly with aqueous pKa are those which are also
most accurately reflecting the extent of delocalization between
the two bonded atoms. Including the VCNxc vs. bond lengths for
our outliers, 13a, 15a, 16a and 17a, shows that they do not
diverge substantially from the highly correlated lines of the best
fit for either C–N(im) or N–C(Ph). Correspondingly, these four
compounds remain as outliers for the plot of VCNxc values vs. pKa
for C–N(im), and as observed for the bond lengths, fall within
the expected region of the plot for VCNxc values vs. pKa for N–C(Ph)
(Fig. S4, ESI†).
On the basis of previous work, we suspect that for compounds
with m-halogen and p-nitro substituents (13a and 15a), the
halo-nitro interaction perturbs the charge distribution of the
guanidine fragment to such a degree that the relationship
between C–N(im) and pKa is no longer reflected in the general
trend observed for most other congeners. If more pKa data were
available, it is proposed that we could form a new HiCoS
consisting of only compounds of this type. Currently, in the
absence of an adequate quantity of pKa data, a separate
predictive HiCoS using the C–N(im) bond lengths cannot be
constructed. Given that the N–C(Ph) bond lengths and corres-
ponding V CNxc values do not diverge from the general trend as a
result of the halo-nitro interaction, the C–N(Ph) model should
be used to predict compounds of this type. For two of three
3-pyridyl compounds (16a–18a), an explanation for their 40.5
prediction errors is not immediately accessible in terms of their
structure. This is due to the fact that one 3-pyridyl containing
compound, 18a, has a relatively low error of +0.30 predicted
Fig. 2 (A) Correlation (r2 = 0.993) between experimental pH-metric and
UV-metric pKa values for compounds 3a–23a, 3b, 17b, 18b, 22b, 26b, and
27b. (B) Correlation (r2 = 0.965) between pH-metric pKas and AIBLHiCoS
predicted pKa values for compounds 1a–23a and 1b–27b. (C) Correlation
(r2 = 0.947) between UV-metric pKas and AIBLHiCoS predicted pKa values
for compounds 3a–23a, 3b, 17b, 18b, 22b, 26b, and 27b.
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using the C–N(im) model. We can therefore assert that the
presence of the heteroatom at the 3-position is not the sole
cause of the higher pKa values we predict, based on their longer
C–N(im) bond lengths. Once again, in the absence of an
adequate amount of experimental data for like compounds at
the time of writing, we cannot prove indefinitely that these
compounds would form their own subset. We therefore suggest
that future predictions for all 3-pyridyl compounds be made via
implementation of the N–C(Ph) model equation.
2.3.2. Guanidines. For the guanidine test set, the only
AIBLHiCoS prediction above 1 unit corresponds to 22b, 1-(5-
chloro-2-pyridinyl)guanidine. Ourmodel gives an error of +1.05 units
whereas ChemAxon gives an error of 0.89. There are no pyridinyl-
type compounds within the training set, but two 3-pyridinyls, 17b
and 18b, return respectable errors of +0.55 and 0.24 using
the CQN model. pKa data for 1-(2-pyridinyl)guanidine and
1-(6-methyl-2-pyridinyl)guanidine are available, and when the
bond lengths of their optimised structures are included in our
CQN vs. pKa plot using tautomer A (shown in Fig. S2 of the
ESI,† bond labelled ii), they also appear below the line of the
best fit, near the data point for 22b. When predicted using
the model equation, errors of +1.51 and +1.22 units are
observed. It appears that the presence of the heteroatom at
the 2-position of the aryl group causes further partitioning of
the set once again. A new HiCoS cannot be constructed using
only two data points, and so a predictive equation which would
better describe the LFER for these compounds cannot be
formulated until more pKa data become available.
Boltzmann weighting of tautomers according to either internal
or Gibbs energies at the level of theory used to obtain the bond
lengths for the AIBLHiCoS protocol reveals a general prevalence
of the ‘‘imino’’ tautomer for both sets of guanidines and
imidazolidines. This tautomer is characterised by a CQN double
bond between the central carbon atom of the Y-shaped guanidine
Fig. 3 Substituent eﬀects on the pKa of 2-(arylimino)imidazolidines and arylguanidines. The pKa values were determined using potentiometric titrations
at 25 1C. DpKa is the diﬀerence in pKa of the substituted compound with respect to the unsubstituted compound (1a, 1b, 19a, and 16a, respectively).
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fragment and the nitrogen adjacent to the phenyl group. For
imidazolidines, the optimal model emerges from one of the C–N
bond lengths of the 5-membered ring of this most stable tautomer.
The emergence of the optimal model from the most stable
tautomer is therefore congruent with it being the dominant
species in solution, confirmed by the energetics. In terms of the
ChemAxon predictions, using the most stable tautomer as an
input structure allows for better prediction accuracy for both the
imidazolidines and guanidines. However, for AIBLHiCoS the best
internal validation statistics for guanidines are revealed using
equilibrium bond lengths from a specific conformation of a higher
energy tautomeric form, which is not in agreement with the energy
rankings. Regardless of that these results corroborate those of our
previous work,27 which states that in the case of guanidines
conformational commonality undermines stability; that is to say,
as long as the compound of interest containing the guanidine
group is optimised from this specific form, a very high degree of
prediction accuracy may be obtained.
2.4. Quantitative eﬀect of aryl substituents on the pKa of aryl
guanidines and 2-(arylimino)imidazolidines
According to a survey by Manallack on the pKa distribution of
drugs,24 no CNS drug has a pKa of above 10.5. Thus, phenyl-
guanidine (1b: pKa = 10.90), the reference compound in our
study, is unlikely to have good CNS activity. Replacing the
guanidine group of 1b by a 2-iminoimidazolidine group (1a:
pKa = 10.24) leads to a drop in the basicity of the molecule
(DpKa = 0.66). Changing the phenyl ring of 1a for a 2-pyridinyl
(19a) or a 3-pyridinyl (16a) group has a strong eﬀect on the pKa
decrement (DpKa = 0.79 and 1.25, respectively). The eﬀect
of electron-donating and electron-withdrawing groups on
the pKa of 2-(arylimino)imidazolidines and arylguanidines is
summarized in Fig. 3 and Table S6 (ESI†). As expected, these
eﬀects depend mainly on the capacity of these substituents to
donate or withdraw electrons from the aryl ring, resulting in higher
or lower electron density on the 2-imino nitrogen, respectively.
A linear relationship was found between the pKa values and
the Hammett s values of meta and para substituents as shown
in Fig. 4.39,40 For para-amino substituents conjugated with the
imidazolidine nitrogen (2a, 2b, 24b), sp
 values were used to
get a good correlation. In contrast, compounds with an amide
group (9a) in para position correlated poorly with the Hammett
constant (red points in Fig. 4).
Amino substituents (18a, 18b, 24b) in the para-position to
the guanidine/imidazoline group yield the strongest pKa
increase (DpKa = +1.11 to 1.34), with the exception of the
aminophenyl group (2a, 2b), the electron donating capacity of
which is much reduced by the presence of the phenyl ring
(DpKa = +0.25 to 0.46). Expectedly, the pKa of the pyridine
nitrogen is influenced to a larger extent by the presence of
amino and alkyl electron-donating substituents (DpKa = +1.31
and +1.92 for 17a and 18a, respectively). Alkoxy substituents
(8a, 26b, 27b) have a smaller eﬀect on the pKa increase
(DpKa = +0.06 to 0.38) with respect to the phenoxy group (25b:
DpKa = +0.78). For electron-withdrawing substituents, the pKa
decrement follows this order: 4-PhNHCOo 4-Aco 4-NO2o (3-
Cl,4-NO2) o (3-F,4-NO2) o (2-F,4-NO2) o (2Cl,4-NO2). The
addition of one halogen atom on the aryl ring results in pKa
decrements of 0.45 (3-Cl), 0.72 (3-F), 1.11 (2-F), and 1.23 (2-Cl).
These values are consistent with the pKa decrements measured
for a series of chloro- and fluoro-substituted bis-2-(arylimino)-
imidazolidines reported previously.22
Timmermans et al. have shown that the presence of two
chlorine atoms in the position ortho to the 2-imino nitrogen
reduces the pKa value of the molecule by 1.66 units (e.g. 4-nitro-
clonidine: pKa = 6.86 at 20 1C).
41 According to the pKa values
reported by Rozas and co-workers for a series of symmetric and
unsymmetrical bisguanidines and bis-2-(phenylimino)imidazo-
lidines,42,43 the addition of a 4-imidazoline or 4-guanidine group on
the phenyl substituent of 2a–b and 3a–b results in a pKa decrement
of approximately 0.50 units with respect to 2a–b and 3a–b. The
values of DpKa with respect to 1a–b are shown in Fig. 5.
3. Conclusions
Arylguanidines and 2-(arylimino)imidazolidines whose pKa values
are reported here belong to a pharmacologically important class of
molecules with promising applications as centrally active a2-AR
modulators. As the ionisation constant is a key physicochemical
parameter that governs the membrane permeability of drugs (e.g.
the BBB permeability in the case of CNS active compounds), the
data of substituent eﬀects on the basicity of arylguanidines and
2-(arylimino)imidazolidines can be useful for the design of new
molecules of this class.
The dissociation constants of 23 arylguanidines and 12
2-(arylimino)imidazolidines measured using the spectrophoto-
metry method were consistent with those measured using
potentiometric titrations, further validating the 96-well micro-
titre plate method32 as a useful tool for the medium throughput
determination of pKa of series of molecules.
Finally, we have shown that the AIBLHiCoS method is useful
to predict the pKa values of aryl guanidines and 2-(arylimino)-
imidazolidines with low RMSD values, using only a single bond
length obtained at a low level of theory. It must be noted that
compound 12a is an excellent example of the predictive power
Fig. 4 Relationship between experimental pKa (determined by potentio-
metric titrations at 25 1C) and S Hammett s constants39 for meta and para
substituents of 2-(arylimino)imidazolidines (K) and arylguanidines (m).
Compounds that deviate significantly from the bottom (right) linear rela-
tionship appear in red (9a).
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of the AIBLHiCoS model. The initial (pH-metric) pKa value we
were working with was 8.13, meaning that our prediction of
7.28 was 0.85 units out, whilst for 14a, the 2-fluoro analogue,
the prediction error was only 0.19. Re-measurement of the pKa
value for 12a then revealed the first to be erroneous, for reasons
that are not clear, and the new pKa value was observed to be
7.29, only 0.01 units out from the prediction. This value was
also in excellent agreement with the UV-metric pKa value (7.33).
4. Experimental
Chemistry
Melting points were measured in open capillary tubes using a
Stuart Scientific SMP3 apparatus or a Mettler Toledo MP70
melting point system and are uncorrected. LC-MS spectra were
recorded on a WATERS apparatus integrated with a HPLC
separation module (2695), a PDA detector (2996) and a Micro-
mass ZQ spectrometer. Analytical HPLC was performed with a
SunFire C18–3.5 mm column (4.6 mm  50 mm). Mobile phase
A: CH3CN + 0.08% formic acid and B: H2O + 0.05% formic acid.
UV detection was carried over 190 to 440 nm. Accurate mass
was measured with an Agilent Technologies Q-TOF 6520 spec-
trometer using electrospray ionisation. 1H NMR and 13C NMR
spectra were registered on Bruker Avance-300, Varian Inova-400,
and Varian-system-500 spectrometers. Chemical shifts of the
1H NMR spectra were referenced to the residual proton reso-
nance of the deuterated solvents: D2O (d 4.79) and CD3OD
(d 3.31). Chemical shifts of the 13C NMR spectra were internally
referenced for D2O and CD3OD (d 49.0). Coupling constants J are
given in hertz (Hz).
Synthesis of phenylguanidines (1b, 2b, 3b, 6b, 7b, and
24–27b) and 2-(phenylimino)imidazolidines (2a–10a, and 23a)
as trifluoroacetate salts. The di-Boc-protected precursor7 (typical
scale: 5 to 25 mg) was dissolved in CH2Cl2 (1 mL) and CF3CO2H
(0.5 mL) was added. The reaction was stirred for 4 h at room
temperature and the volatiles were evaporated. Et2O was added
to the crude residue and evaporation was repeated. The TFA
salts were obtained by precipitation from hexane/Et2O (guanidines)
or hexane (2-aminoimidazolines). The precipitates were rinsed
with hexane and dried under high vacuum over P2O5 to yield the
TFA salts as brownish hygroscopic solids. 1H NMR spectra were
consistent with the reported data.7 Most of the compounds were
Z95% pure, or 490% (4a, 5a, 6a, 8a, and 6b, 7b) as checked
using HPLC-MS.
Synthesis of compounds 1a and 11a–15a. A Kimax tube
charged with the aniline reagent (0.4 mmol, 1 equiv.) and
methyl 2-(methylthio)-4,5-dihydro-1H-imidazole-1-carboxylate31
(0.5 mmol, 1.25 equiv.) in glacial acetic acid (1.2 mL) was heated
at 70 1C (1 day for 1a and 13a, 3 days for 11a and 15a) or 90 1C
(4 days, 12a and 14a), until the formation of the methyl
2-(phenylamino)-4,5-dihydro-1H-imidazole-1-carboxylate inter-
mediate. Then, methanol was added (1 mL) and the reaction was
heated at 100 1C for 2 days (1a, 11a, 13a, 15a) or 80 1C for
4 days (12a, 14a). The solvent was evaporated under vacuum and
the acetate salt of the product was isolated using silica chromato-
graphy (Isolute prepacked column, 2g). The non-polar starting
materials were first eluted with 100% CH2Cl2, then the products
were obtained with CH2Cl2 :MeOH (10 :1) (compounds 1a, 11a, 13a,
15a) or CH2Cl2 :MeOH (15 :1- 10 :1) (compounds 12a and 14a).
N-Phenyl-4,5-dihydro-1H-imidazol-2-amine acetate salt (1a).
Yellowish gum (88%). HPLC (UV) 492%. dH (300 MHz, D2O) d
7.44 (dq, J 2.9, 4.3, 6.0, 2H), 7.39–7.30 (m, 1H), 7.29–7.21 (m,
2H), 3.71 (s, 4H), 1.86 (s, 3H, AcO). dC (75 MHz, D2O) d 181.8
(AcO), 159.2, 135.4, 130.2, 127.8, 124.7, 43.0, 23.6 (AcO). MS
(ESI+) m/z 162 (M + H)+.
N-(4-Nitrophenyl)-4,5-dihydro-1H-imidazol-2-amine acetate
salt (11a). Yellow-orangish solid (14%). Mp 190.2–193.1 1C.
Fig. 5 Substituent eﬀects on the pKa of bis(2-(phenylimino)imidazolidines) and bisguanidines. Reported pKa values determined using potentiometric
42
or UV-spectrophotometric43 titrations at 25 1C. DpKa is the diﬀerence in pKa of the 4-substituted compound with respect to 1a or 1b.
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HPLC (UV)495%. dH (300 MHz, D2O) d 8.30 (d, J 9.1, 2H), 7.43
(d, J 9.1, 2H), 3.80 (s, 4H), 1.90 (s, 3H, AcO). dC (75 MHz, D2O) d
181.8 (AcO), 158.6, 145.1, 143.6, 125.9, 123.2, 43.1, 23.6
(AcO). MS (ESI+) m/z 207 (M + H)+. HRMS (ESI+) m/z
206.0805 (C9H10N4O2 requires 206.0804).
N-(2-Chloro-4-nitrophenyl)-4,5-dihydro-1H-imidazol-2-amine
acetate salt (12a). Yellow solid (5%). Mp 4195 1C. HPLC (UV)
495%. dH (400 MHz, D2O) d 8.54 (d, J 2.5, 1H), 8.30 (dd, J 2.5,
8.8, 1H), 7.73 (d, J 8.8, 1H), 3.85 (s, 4H), 1.95 (s, 3H, AcO). MS
(ESI+) m/z 241, 243 (M + H)+. HRMS (ESI+) m/z 240.0413
(C9H9ClN4O2 requires 240.0414).
N-(3-Chloro-4-nitrophenyl)-4,5-dihydro-1H-imidazol-2-amine
acetate salt (13a). Yellow solid (26%). Mp 156.5–160.3 1C. HPLC
(UV) 495%. dH (300 MHz, D2O) d 8.10 (d, J 8.8, 1H), 7.55 (d,
J 2.4, 1H), 7.35 (dd, J 2.4, 8.8, 1H), 3.81 (s, 4H), 1.89 (s, 3H,
AcO). dC (75 MHz, D2O) d 181.7 (AcO
), 158.3, 144.4, 141.6, 128.8,
128.2, 125.4, 121.6, 43.1, 23.6 (AcO). MS (ESI+) m/z 241, 243 (M +
H)+. HRMS (ESI+) m/z 240.0417 (C9H9ClN4O2 requires 240.0414).
N-(2-Fluoro-4-nitrophenyl)-4,5-dihydro-1H-imidazol-2-amine
(14a). Yellow solid (28%). Mp 220–226 1C. HPLC (UV)495%. dH
(500 MHz, methanol-d4) d 7.95 (dd, J 2.5, 8.7, 1H), 7.92 (dd,
J 2.5, 10.7, 1H), 7.20 (t, J 8.7, 1H), 3.55 (s, 4H). dC (126 MHz,
methanol-d4) d 161.9, 156.2 (d, J 246.6), 146.9 (d, J 11.5), 142.7
(d, J 8.7), 125.7 (d, J 3.3), 121.4 (d, J 3.0), 112.6 (d, J 25.9), 43.5.
MS (ESI+) m/z 225 (M + H)+. HRMS (ESI+) m/z 224.0706
(C9H9FN4O2 requires 224.0710).
N-(3-Fluoro-4-nitrophenyl)-4,5-dihydro-1H-imidazol-2-amine
acetate salt (15a). Yellow solid (24%). Mp 197.3–200 1C. HPLC
(UV) 495%. dH (300 MHz, D2O) d 8.20 (t, J 8.7, 1H), 7.30 (dd,
J 2.4, 12.5, 1H), 7.25–7.15 (m, 1H), 3.82 (s, 4H), 1.88 (d, J = 3.8,
3H). dC (75 MHz, D2O) d 181.7 (AcO
), 158.4, 156.5 (d, J 242.5),
143.8 (d, J 13.1), 134.0 (d, J 9.4), 128.4, 118.0, 111.6 (d, J 24.6),
43.1, 23.5 (AcO). MS (ESI+) m/z 225 (M + H)+. HRMS (ESI+) m/z
224.0707 (C9H9FN4O2 requires 224.0710).
Potentiometric pKa determination. Titrations were carried
out at 25  0.5 1C in 0.15 M aqueous KCl solution under a
nitrogen atmosphere using a SiriusT3 apparatus (Sirius Analytical
Instruments Ltd, East Sussex, UK) equipped with an Ag/AgCl
double junction reference pH electrode and a turbidity sensor.
Standardised 0.5 M KOH and 0.5 M HCl were used as titration
reagents. The KOH solution was standardized by potassium acid
phthalate. The pKa values are the mean of 3 titrationsSD except
otherwise noted.
Spectrophotometric pKa determination. The UV-spectra
were recorded at 30 1C (i.e. room temperature) with a Thermo
Multiskan spectrum apparatus using the 96-well microtiter
plate method as described,32 with the following modifications:
(1) compounds’ stock solutions were prepared in DMSO at
C = 5 mM to ensure that the maximum absorbance of the
compound was below 1.5 AU (i.e. the final concentration of the
compound in the well was 0.1 mM). (2). The buﬀer solutions of
constant ionic strength (0.1 M KCl) were prepared according to
http://www.biomol.net/en/tools/buﬀercalculator.htm: (a) 25 mM
phosphate buﬀer (pH 2.01, 2.54, 7.0, 7.27, 7.61, 7.94, 11.50, 11.80,
and 12.40), (b) 25 mM citrate buﬀer (pH 3.23), (c) 25 mM acetate
buﬀer (pH 4.17 and 4.61), (d) 25mMMES buﬀer (pH 5.12, 5.66, 6.01,
6.19, 6.42, 6.62, and 6.78), (e) 25 mM ethanolamine buﬀer (pH 8.88,
9.17, 9.23, 9.66, 9.74, 10.13, and 10.32). The pH of the buﬀer
solutions was measured at 30 1C (i.e. working temperature).
The raw UV data were processed using the Excel program
(see the Excel sheet template in the ESI†) and the pKa values
were determined by linear regression from the total absorbance
vs. pH curve as reported.32 The pKa values are the mean of 3 or
4 experiments (expressed as Ka values)  SD.
Gas-phase ab initio calculations
The initial structures of each member of the respective training
sets (guanidines and 2-(phenylamino)imidazolidines) were
built using the program GaussView in each available tautomeric
form. This equates to three tautomers for the imidazolidines,
labelled T1–T3 in Fig. S1 (ESI†) and five ‘‘tautomers’’ for
guanidines, labelled A–E in Fig. S2 (ESI†). For compounds with
higher degrees of conformational freedom, several starting
structures were generated using the ‘‘Conformers’’ plug-in
within Marvin Sketch by ChemAxon.35 Geometry optimization
in the gas-phase was then performed for each conformer of each
compound in each of the tautomeric forms using the GAUSSIAN09
program.44 Calculations were initially carried out at the B3LYP/6-
31G(d,p) level but the basis set was changed to 6-311G(d,p) for
reasons that will be explained below. For biguanide derivatives
included in the guanidine training set, various tautomeric
forms of the guanidine fragment present within the R group
were considered, whilst maintaining the specific tautomeric
form of the guanidine fragment under consideration. Frequency
calculations were carried out on optimised structures again using
GAUSSIAN09, at the same level of theory. The output files were
then inspected to confirm the absence of negative eigenvalues
after diagonalization of the Hessian matrix, so that geometries
are confirmed as true energy minima. Where a number of
starting conformers of a tautomer were generated, the most
stable conformer was chosen by comparing the total energies
of each optimised structure. At this point we noticed that the chosen
basis set was causing an issue in terms of ranking conformer
stability between 2-(2-halogen-phenylimino)imidazolidine geo-
metries with and without IHBs. These IHBs are seen to exist
between an N–H group on imidazolidine and the o-halogen
atom on benzene, and are ubiquitous throughout the most
stable conformations of all compounds containing this substituent
for tautomer T3, with the exception of 2-(2,4-Cl-phenylimino) and
2-(2,5-Cl-phenylimino)imidazolidine. This observation prompted
the re-optimisation of all T3 training set compounds at the B3LYP/
6-311G(d,p) level of theory. Using the valence triple zeta basis set
revealed a consistent picture, where the presence of an IHB is a
stabilising feature for all compounds. At this point all other
calculations for T1 and T2 and tautomers A–E of the guanidine
training set were also repeated for consistency. All analysis
corresponds to the results of the calculations using the 6-311G(d,p)
basis set.
Seven bond lengths were extracted from each imidazolidine
compound, corresponding to each of the three CN bonds of the
guanidine fragment, in addition to the N–C(Ph) bond connecting
imidazolidine to benzene and the N–C, C–C and C–N bonds of
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the imidazolidine ring. These are labelled a–g in Fig. S1 of the
ESI.† Five bond lengths from within the guanidine moiety were
also extracted, which correspond to the two CN single and one
CN double bond of the guanidine group, the N–H bond attached
to the imine nitrogen in A, B, D and E, and one N–H bond of a
primary amine group. These are labelled i–v, in Fig. S2 (ESI†). The
five bond lengths i–v within tautomers A–E were then regressed
against the pKa values for the set of guanidines. The seven bond
lengths a–g of the three tautomers T1–T3 were also regressed
against their pKa values for the set of 2-(phenylimino)imidazoli-
dines. The squared correlation coefficient (r2), Root-Mean-Squared
Error of Estimation (RMSEE) and leave-one-seventh-out q2 values
were obtained using the program SIMCA-P 10.0.45
By a comparison of internal and external validation metrics
obtained for each bond length model, an optimal linear equation
was chosen. For guanidines, the model was constructed using the
CQN bond lengths of training set compounds as tautomer A,
labelled ii in Fig. S2 (ESI†). For imidazolidines, the model was
constructed using an endocyclic C–N bond length of the imino
tautomer T3, labelled ‘‘a’’ in Fig. S1 (ESI†). The predictions for
test set compounds 1a–23a (2-(phenylimino)imidazolidines) and
1b–27b (aryl guanidines) were obtained by energy minimization,
(via a conformational search using Marvin followed by geometry
optimisation), frequency calculations, and insertion of the
appropriate bond length into the linear equation for the
optimal bond length vs. pKa model. The test compounds were
constructed in the same tautomeric form as those of the training
set used to construct the model.
The program AIMAll (version 14.04.17)46 was used to carry
out QTAIM analysis and the IQA partitioning calculations to
obtain Vxc values for the atomic interactions corresponding to
the C–N(im) and N–C(Ph) bonds. Calculations were carried out
on B3LYP/6-311G(d,p) wavefunctions of the following species:
the five nitro compounds (11a–15a), compound 11 of the
training set and five compounds for which no pKa data exists,
2-(3-Cl-phenylimino), 2-(3-F-phenylimino), 2-(3,5-Cl2-4-NO2-
phenylimino), 2-(3-Br-4-NO2-phenylimino) and 2-(3-F,5-Cl-4-NO2-
phenylimino)imidazolidine. For the five additional compounds,
optimisation and frequency calculations were also performed
at the B3LYP/6-311G(d,p) level before AIMAll analysis and the
relevant bond lengths were extracted.
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